CDK19 and prostate carcinoma: After these two subtypes of prostate cancer, gene amplification of one or more of CDK8, CDK19, and CCNC was most common in several subtypes of cancers of the GI tract (tubular stomach adenocarcinoma (5%), colon adenocarcinoma (3.9%), intestinal type stomach adenocarcinoma (3.7%), rectal adenocarcinoma (3.6%)), as well as dedifferentiated liposarcoma (4.8%), bladder/urinary tract cancer (4.11%), and breast invasive ductal carcinoma (3%) (Figure 3).